Amyloid Imaging with [11C]PIB PET and MRI in MCI – a pilot study - MCI and PIB

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-020724-21-AT

Enrollment

Unknown

Registered

2011-02-10

Start date

2011-04-06

Completion date

Unknown

Last updated

2016-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Mild Cognitive Impairment (MCI) will be investigated with PIB PET to determin amyloid pathology

Interventions

Product Name: [11C]PIB Product Code: 123 Pharmaceutical Form: Radiopharmaceutical precursor Concentration unit: MBq megabecquerel(s) Concentration type: up to Concentration number: 400-440

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age range between 60-80 years, male and female Neuropsychological Testing with diagnosis of Mild Cognitive impairment – amnestic or non amnestic type (single and multiple domain). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: major life threatening internal diseases, for example heart failure, cancer, .. major neurological diseases except MCI, for example major stroke, parkinsonism major psychiatric diseases except dementia, for example major depression

Design outcomes

Primary

Measure	Time frame
Main Objective: Patients with Mild Cognitive Impairment (MCI) will be investigated with PIB PET to visualize amyloid pathology; conversion to Alzheimer´s disease within 2 years will be determined, and dependency on (coexisting) cerebral small vessel disease in cerebral MRI will be obtained. ;Secondary Objective: amyloid pathology in different MCI types; ;Primary end point(s): neuropsychological testing two years after PIB PET and determination of dementia type and MCI respectively	—

Measure

Time frame

Main Objective: Patients with Mild Cognitive Impairment (MCI) will be investigated with PIB PET to visualize amyloid pathology; conversion to Alzheimer´s disease within 2 years will be determined, and dependency on (coexisting) cerebral small vessel disease in cerebral MRI will be obtained. ;Secondary Objective: amyloid pathology in different MCI types; ;Primary end point(s): neuropsychological testing two years after PIB PET and determination of dementia type and MCI respectively

—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026